arsenic trioxide

(redirected from Trisenox)
Also found in: Dictionary, Thesaurus, Medical.

arsenic trioxide

[′ärs·ən·ik ‚tri′äk‚sīd]
(inorganic chemistry)
As2O3 A toxic compound, slightly soluble in water; octahedral crystals change to the monoclinic form by heating at 200°C; occurs naturally as arsenolite and claudetite; used in small quantities in some medicinal preparations. Also known as arsenic oxide; arsenious acid.
References in periodicals archive ?
The milestone will be paid pursuant to an acquisition agreement for Trisenox previously entered into with Teva.
According to CTI BioPharma Corp, the expected milestone payment is related to the US Food and Drug Administration's approval of TRISENOX (arsenic trioxide) for first line treatment of acute promyelocytic leukemia.
TRISENOX was reportedly acquired from CTI BioPharma by Cephalon Inc, which was subsequently acquired by Teva.
In a previous agreement, TRISENOX was acquired from CTI BioPharma by Cephalon, which was subsequently acquired by Teva.
TRISENOX is indicated for the induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation of PML/RAR-alpha gene expression.
Trisenox is currently indicated for second line treatment of patients, who have not responded to treatment with retinoids and chemotherapy, or when their disease has returned after this type of treatment.
Biopharmaceutical company CTI BioPharma (NASDAQ:CTIC)(MTA:CTIC) reported on Thursday the receipt of USD15m milestone payment from Teva Pharmaceutical Industries related to the achievement of sales milestones for TRISENOX (arsenic trioxide).
Establishing a commercial presence in Europe is part of Cell Therapeutics' strategic plan to expand the clinical development and sales of TRISENOX," stated James A.
Biopharmaceutical company Cell Therapeutics Inc (NASDAQ:CTIC)(MTA:CTIC) reported on Monday the receipt of a USD5m milestone payment related to the achievement of a sales milestone for TRISENOX (arsenic trioxide).
TEVA ) associated to the attainment of a sales milestone for TRISENOX (arsenic trioxide).
M2 EQUITYBITES-December 2, 2013-Cell Therapeutics Inc wins USD5m milestone payment for TRISENOX
According to Hoover's, CTIC's flagship product, Trisenox, has been approved by the FDA to combat a certain type of leukemia.